Ophthalmology Times: Tepezza Receives Approval in Japan for Active Thyroid Eye Disease Treatment
Ophthalmology Times: Revolutionary Change in TED Treatment
Amgen has announced that Tepezza (teprotumumab [Genetical Recombination]) has received approval from Japan's Ministry of Health, Labour and Welfare for treating active thyroid eye disease (TED) or TED with a high clinical activity score (CAS).
TEPEZZA is the first and only medication approved in Japan for the treatment of active TED.
Patient Impact and Ongoing Research
In Japan, an estimated 25,000 to 35,000 individuals are affected by TED, comprising both active and chronic (low CAS) forms. A separate phase 3 trial (jRCT2031220730) is currently ongoing to evaluate the efficacy of Tepezza in patients with chronic TED and low CAS.
- Tepezza provides a critical option for patients.
- Promising ongoing research may further expand treatment options.
Disclaimer: The information provided on this site is for informational purposes only and is not intended as medical advice. We are not responsible for any actions taken based on the content of this site. Always consult a qualified healthcare provider for medical advice, diagnosis, and treatment. We source our news from reputable sources and provide links to the original articles. We do not endorse or assume responsibility for the accuracy of the information contained in external sources.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.